Study of Dato-Dxd as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumours (TROPION-PanTumor03)

Study identifier:D926UC00001

ClinicalTrials.gov identifier:NCT05489211

EudraCT identifier:2022-000776-19

CTIS identifier:2023-509436-26-00

Recruiting

Official Title

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours

Medical condition

endometrial cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Leucovorin LV, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin

Sex

All

Estimated Enrollment

582

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 06 Sept 2022
Estimated Primary Completion Date: 19 Aug 2026
Estimated Study Completion Date: 19 Aug 2026

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Daiichi Sankyo

Inclusion and exclusion criteria